Natera (NASDAQ:NTRA) Given New $200.00 Price Target at Piper Sandler

Natera (NASDAQ:NTRA) had its target price boosted by Piper Sandler from $150.00 to $200.00 in a research report report published on Monday morning,Benzinga reports. They currently have an overweight rating on the medical research company’s stock.

Other equities analysts also recently issued research reports about the company. The Goldman Sachs Group upped their price objective on Natera from $125.00 to $140.00 and gave the company a “buy” rating in a research report on Wednesday, October 16th. BTIG Research upped their price objective on Natera from $125.00 to $135.00 and gave the company a “buy” rating in a research report on Friday, August 9th. StockNews.com downgraded Natera from a “hold” rating to a “sell” rating in a research report on Thursday, November 14th. UBS Group cut their price objective on Natera from $160.00 to $145.00 and set a “buy” rating on the stock in a research report on Friday, August 9th. Finally, Morgan Stanley upped their price objective on Natera from $132.00 to $176.00 and gave the company an “overweight” rating in a research report on Thursday, November 14th. One equities research analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $140.59.

Natera Stock Performance

NASDAQ NTRA opened at $153.42 on Monday. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. The business’s 50 day moving average price is $127.38 and its 200-day moving average price is $115.76. Natera has a fifty-two week low of $53.31 and a fifty-two week high of $167.79.

Natera (NASDAQ:NTRA) last released its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.31. The firm had revenue of $439.80 million for the quarter, compared to the consensus estimate of $361.43 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The company’s revenue for the quarter was up 63.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.95) EPS. On average, analysts forecast that Natera will post -1.7 earnings per share for the current year.

Insider Buying and Selling at Natera

In other Natera news, CEO Steven Leonard Chapman sold 5,024 shares of the firm’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $128.48, for a total value of $645,483.52. Following the completion of the sale, the chief executive officer now owns 195,686 shares of the company’s stock, valued at approximately $25,141,737.28. This trade represents a 2.50 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Gail Boxer Marcus sold 2,212 shares of the firm’s stock in a transaction dated Thursday, November 14th. The stock was sold at an average price of $158.53, for a total value of $350,668.36. Following the completion of the sale, the director now directly owns 19,386 shares of the company’s stock, valued at approximately $3,073,262.58. This represents a 10.24 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 36,821 shares of company stock worth $4,776,878. 7.60% of the stock is owned by insiders.

Institutional Investors Weigh In On Natera

A number of institutional investors and hedge funds have recently modified their holdings of NTRA. Wellington Management Group LLP lifted its holdings in shares of Natera by 205.4% during the third quarter. Wellington Management Group LLP now owns 2,800,263 shares of the medical research company’s stock worth $355,493,000 after purchasing an additional 1,883,481 shares during the period. Farallon Capital Management LLC lifted its holdings in shares of Natera by 13.6% during the second quarter. Farallon Capital Management LLC now owns 4,460,557 shares of the medical research company’s stock worth $483,034,000 after purchasing an additional 532,874 shares during the period. First Light Asset Management LLC lifted its holdings in shares of Natera by 295.9% during the first quarter. First Light Asset Management LLC now owns 656,708 shares of the medical research company’s stock worth $60,063,000 after purchasing an additional 490,822 shares during the period. AQR Capital Management LLC lifted its holdings in shares of Natera by 257.6% during the second quarter. AQR Capital Management LLC now owns 651,523 shares of the medical research company’s stock worth $70,553,000 after purchasing an additional 469,327 shares during the period. Finally, PointState Capital LP lifted its holdings in shares of Natera by 112.0% during the third quarter. PointState Capital LP now owns 782,538 shares of the medical research company’s stock worth $99,343,000 after purchasing an additional 413,468 shares during the period. Institutional investors and hedge funds own 99.90% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.